Product name as reported
Casirivimab Imdevimab: adverse event reports filed with FDA
1,778 reports list it as a suspect or interacting product, 2020–2025.
- 1,778
- reports as suspect product
- 0% of all reports · about 319 a year
- 1
- reports, 12 months to June 2026
- 12 in the 12 months before
- 67%
- marked serious by the reporter
- 57.4% across all reports
- 2.8%
- record death among outcomes, as reported
- 50 reports · not verified by FDA
1,778 adverse event reports received by FDA list the product name "Casirivimab Imdevimab" as reporters wrote it as a suspect or interacting product, from December 2020 to October 2025. A further 110 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 1 report listed it, down 92% from 12 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 319 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded dyspnoea (15.3%), infusion related reaction (13.8%) and incorrect dose administered (9.7%). A report can list several reactions, so shares add to more than 100%; 357 different terms appear across these reports. Dyspnoea is recorded in 15.3% of these reports, against 2.7% of all reports in the database.
67% of the reports are marked serious by the reporter; 2.8% record death among the outcomes and 32% record hospitalisation, as reported. 50.2% of the reports came from pharmacists, and the largest patient age group is 45 to 64 (29.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
Reactions recorded in the reports
share of Casirivimab Imdevimab reports recording the termall reports in the database
- Dyspnoeashortness of breath15.3%272
- Infusion related reactiona reaction during or soon after an infusion13.8%246
- Incorrect dose administeredthe wrong dose was given9.7%173
- Nauseafeeling sick8.8%157
- Oxygen saturation decreased8.7%155
- Dizzinesslight-headedness or unsteadiness7.3%129
- Chest discomfortchest discomfort6.6%117
- Coughcough6.4%114
- Flushingsudden reddening or warmth of the skin6%106
- Pyrexiafever5.8%104
- Hypoxialow oxygen4.9%88
- Chillschills or shivering4.6%82
- COVID-19 pneumonia4.6%81
- Hypotensionlow blood pressure4.4%79
- Vomitingbeing sick4.3%77
- Chest painchest pain4.2%75
- Incorrect route of product administrationthe product was given by the wrong route4.2%75
- Product storage errorthe product was stored wrongly4.1%73
- Back painback pain4%72
- Hyperhidrosisexcessive sweating3.9%70
- Headachehead pain3.6%64
- Feeling hotfeeling hot3.4%60
- Erythemaskin redness3.3%58
- Tachycardiafast heart rate3.3%58
- Urticariahives3.1%56
- Fatiguetiredness3.1%55
- Tremorshaking3.1%55
- Blood pressure increaseda raised blood pressure reading3%53
Top 30 of 357 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 96.1% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Covid-19 | 1,213 | 68.2% |
| Covid-19 treatment | 115 | 6.5% |
| Covid-19 prophylaxis | 40 | 2.2% |
| Sars-cov-2 test positive | 21 | 1.2% |
| Covid-19 pneumonia | 15 | 0.8% |
| Post-acute COVID-19 syndrome | 11 | 0.6% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,778 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Casirivimab Imdevimab reports |
|---|---|---|
| Acetaminophen | 59 | 3.3% |
| Dexamethasone | 56 | 3.1% |
| Atorvastatin | 53 | 3% |
| Albuterol | 51 | 2.9% |
| Aspirin | 48 | 2.7% |
| Pantoprazole | 37 | 2.1% |
| Prednisone | 37 | 2.1% |
| Amlodipine | 34 | 1.9% |
| Ondansetron | 34 | 1.9% |
| Lisinopril | 30 | 1.7% |
Other products listed in reports where Casirivimab Imdevimab is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Casirivimab Imdevimab | All reports |
|---|---|---|
| Reports as suspect product | 1,778 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 1 | 1,332,454 |
| Marked serious | 67% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 28 | 91 |
| Hospitalisation recorded, per 1,000 reports | 320 | 213 |
| Consumer-filed share | 12.8% | 45.8% |
| Top term, share of reports | Dyspnoea 15.3% | 2.7% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Casirivimab Imdevimab reports
How many adverse event reports has FDA received for Casirivimab Imdevimab?
1,778 reports list Casirivimab Imdevimab as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 1 of them arrived in the latest 12 months. Another 110 list it only as a concomitant medication.
What reactions are recorded in Casirivimab Imdevimab reports?
dyspnoea (15.3%), infusion related reaction (13.8%), incorrect dose administered (9.7%), nausea (8.8%) and oxygen saturation decreased (8.7%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Casirivimab Imdevimab was responsible.
How serious are the reports?
67% are marked serious by the reporter. Among the outcomes recorded, 2.8% of reports include death and 32% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
pharmacist (50.2%), other health professional (28.3%) and consumer or non-health professional (12.8%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Casirivimab Imdevimab rising?
1 reports in the 12 months to June 2026, down 92% from 12 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Casirivimab Imdevimab was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Casirivimab Imdevimab?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Casirivimab Imdevimab as a suspect or interacting product; reports listing it only as a concomitant medication (110) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.